CCND1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This Target Evaluation Report for CCND1 is generated from PatSnap Life Sciences MCP data workflows, combining Target & Disease MCP biology context with Clinical Trials MCP validation and competitive signals.
For AI teams building biomedical agents, PatSnap Life Sciences MCP Servers provide structured retrieval across target biology, disease context, clinical trials, drug evidence, IP intelligence, and other R&D intelligence sources.
21 Direct drug records from Target & Disease MCP | 15 Development records in target context | 15 Disease associations captured | 2 Clinical trial records from Clinical Trials MCP |
Explore PatSnap Life Sciences MCP Servers for AI agents
Executive View
CCND1 is the regulatory cyclin driving the CDK4 axis
Target & Disease MCP profiles CCND1/cyclin D1 as the regulatory component of cyclin D1-CDK4 complexes that phosphorylate RB-family proteins, release E2F transcription, and integrate mitogenic and antimitogenic signals during G1/S progression.
Direct clinical activity is sparse compared with CDK4/6
The MCP workflow retrieved 21 direct drug records, 15 development records, and 15 disease associations. Clinical Trials MCP returned only 2 direct trial records, suggesting that CCND1 is more often used as a biomarker or pathway node than as a direct drug target.
Clinical examples are early and terminated
The direct trial sample includes briciclib in advanced solid tumors and ON 013105 in lymphoma/acute lymphoid leukemia, both terminated Phase 1 studies. That makes direct CCND1 intervention high-risk without a new modality or biomarker thesis.
IP and strategy view
CCND1 IP should be tied to amplification, mantle-cell lymphoma biology, pathway diagnostics, or synthetic-lethal combinations rather than direct cyclin inhibition alone.
Clinical Validation and Competitive Landscape
Clinical Trials MCP returned 2 registered trial records connected to CCND1. The sample below is used as a directional competitive readout rather than a full regulatory review.
| Trial | Phase | Status |
|---|---|---|
| Briciclib dose-escalation, safety, and pharmacokinetic study in advanced solid tumors | Phase 1 | Terminated |
| ON 013105 safety study in lymphoma and acute lymphoid leukemia | Phase 1 | Terminated |
R&D Strategy Recommendation
CCND1 is better treated as a pathway biomarker and patient-selection variable unless a program has a credible direct-modulation technology or synthetic-lethal strategy.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
